Viridian Therapeutics (NASDAQ:VRDN) & Zicix (OTCMKTS:ZICX) Critical Analysis

Viridian Therapeutics (NASDAQ:VRDN) and Zicix (OTCMKTS:ZICX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Viridian Therapeutics and Zicix, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	0	2	9	0	2.82
Zicix	0	0	0	0	0.00

Viridian Therapeutics presently has a consensus target price of $36.33, suggesting a potential upside of 80.85%. Given Viridian Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Viridian Therapeutics is more favorable than Zicix.

Profitability

This table compares Viridian Therapeutics and Zicix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-85,127.16%	-70.12%	-41.49%
Zicix	N/A	N/A	N/A

Earnings & Valuation

This table compares Viridian Therapeutics and Zicix”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$310,000.00	5,133.32	-$237.73 million	($4.31)	-4.66
Zicix	N/A	N/A	N/A	N/A	N/A

Zicix has lower revenue, but higher earnings than Viridian Therapeutics.

Risk & Volatility

Viridian Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Zicix has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.

Summary

Viridian Therapeutics beats Zicix on 5 of the 8 factors compared between the two stocks.

About Viridian Therapeutics

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

About Zicix

Zicix Corporation, through its subsidiary, Texas Mobile Health, Inc., provides diagnostic medical imaging services in Houston, Texas. It offers cardiac diagnostic services, including echocardiogram, stress testing, carotid ultrasound, and halter and event monitoring services; medical services, such as general medical care, medical care for home health patients, general and immigration physicals, weight reduction, cold laser pain relief treatment, physical therapy, and anti-aging treatment; and MRI, CT, and X-Ray services. The company was formerly known as Bederra Corporation and changed its name to Zicix Corporation on February 8, 2011. Zicix Corporation was founded in 1979 and is based in Houston, Texas.